3 results
Approved WMOCompleted
To determine the toxicity of adding chloroquine in escalating doses in patients with small cell lung cancer to standard therapy.
Approved WMOCompleted
To determine the toxicity of adding chloroquine in escalating doses in patients with small cell lung cancer to standard therapy.
Approved WMOCompleted
Primary Objectivea) Phase I (Safety Run-in) The primary objective of the Phase I Safety Run-in part is to investigate the safety of IO102 in combination with either pembrolizumab alone or pembrolizumab and chemotherapy (carboplatin and pemetrexed)…